CRISPR patent analytics
CENTREDOC patent and licensing data on CRISPR have been used by worldwide Fortune 500 companies, biotech ventures, patent law firms, public organizations, and research institutes in Europe, America and Asia since the first launch of a worldwide CRISPR patent landscape of 90 patent families in 2014 (previously at IPStudies). In the past eight years, our experts have built a unique knowledge of the CRISPR technology patenting by monthly collecting, scientific analyzing and categorizing a total of 13100+ patent families and 310+ licensing agreements (source: August 2022 monthly update).Our unique, independent CRISPR patent analytics findings have been cited by Nature, The Scientist, Quartz, Bloomberg, Fortune and the WIPO magazine, among others.
In the past couple of years, the CRISPR technology development has transitioned from R&D into maturity stage according to a number of patent analytics indicators:
With a regular increase of more than 200 patent families published every month, we see a burst in CRISPR application patents, in particular from China, in all fields ranging from agriculture to therapeutics (see our recent review of the CRISPR patent landscape in the CRISPR Journal special issue on China here).
On the technology side, we have compiled a list of more than 100 variants of CRISPR enzymes beyond the best known Cas9 discovery of 2012, with some commercial players trying to exhaustively claim them to secure as broad an IP exclusivity as possible. The different flavors of RNA guides engineered by multiple research teams worldwide make the navigation into the CRISPR system technology landscape even more complex.
The licensing landscape is also developing faster, with more than 270 deals publicly announced since 2014. In particular, we observed a major increase in the therapeutic market in the past couple of years, a good indicator that the technology is also maturing for human use, in line with the development of clinical trials worldwide (and also some COVID-19 related applications, as developed since the early days of 2020).
We supply our CRISPR IP analytics data to a number of patent law firms and Fortune 500 corporate patent information analysts so that they can easily cross-check and integrate it in their internal analyses. We offer a one-time delivery or a semestrial or yearly subscription to our monthly updates, for the patent data and/or the licensing data. With the acquisition of the patent analytics assets and operations from IPStudies by CENTREDOC in January 2022, IPStudies customers can now benefit from the latest advances in patent multi-categorization and multi-source feeds as developed by Centredoc with the breakthrough RAPID5 patent monitoring suite. In addition, to better fit the increasing needs of our customers to focus on specific areas of the complex CRISPR patent landscape, the Centredoc team of patent information and scientific experts can also provide you with custom consultancy services such as dedicated trainings and data zooms to facilitate your orientation in both the large patent landscape and its companion complex licensing landscape. Examples of zooms are per application (e.g. microorganisms, agriculture), per region (e.g. China) or per technology (e.g. cpf1, base editing technologies). Do not hesitate to contact us for more information.
We offer a yearly subscription to our monthly updates, for the patent data and/or the licensing data. CENTREDOC customers benefit from the latest advances in data multi-categorization and multi-source feeds as developed by CENTREDOC with the breakthrough RAPID5 patent monitoring suite. In addition, to better fit the increasing needs of our customers to focus on specific areas of the complex CRISPR patent landscape, the Centredoc team of patent information and scientific experts can also provide you with custom consultancy services such as dedicated trainings and data zooms to facilitate your orientation in both the large patent landscape and its companion complex licensing landscape. Do not hesitate to contact us for more information.
- Patent monitoring
- CRISPR patents
- CRISPR Licences
- Media monitoring
- CRISPR News
- CHF 9’900.-
- CHF 1’800.-
- CHF 1’800.-
- CHF 8’700.-
- CHF 1’200.-
- CHF 1’500.-
CENTREDOC patent analytics (former IPStudies patent analytics) are independently retrieved, analyzed and compiled from public worldwide patent information sources and databases by our PhD experts. Our findings are quoted on a regular basis by scientific and economic journalists as well as by researchers, patent lawyers, and policy makers. We also present our data in selected public conferences and events as invited speakers. Here is a selection of various international media, theses, articles and public reports quoting the IPStudies and CENTREDOC data and analyses:
- “Gene Editing : CRISPR Breakthroughs Highlight IP Questions“, A. Churi, Keltie LLP, Jan 2023
- “G is for gene-editing: The CRISPR landscape“, A. Pygall and J. Lilir, Stephenson Harwood LLP, Oct. 2022.
- “Analysis of CRISPR Patent Application“, HKT, iNEWS, May 2022.
- “Can Patent Law Keep Up With Science?“, B. Roberts, Fior Reports, Apr. 2022.
- “Patent battles“, C. Watson, Cosmos Magazine, Apr. 2022.
- “Patents on Genome Editing in Canada“, The Canadian Biotechnology Action Network (CBAN), Mar. 2022.
- “Major CRISPR patent decision won’t end tangled dispute“, H. Ledford, Nature, Mar. 2022.
- “L’analyse de brevets biotechs est toujours plus prisée“, La Liberté, Jan. 2022.
- “CRISPR and RNAi Systems: Nanobiotechnology Approaches to Plant Breeding and Protection“, edited by Kamel A. Abd-Elsalam, Ki-Taek Lim – Elsevier, 2021.
- “Prospect patents and CRISPR; rivalry and ethical licensing in a semi-commons environment“, A. Panagopoulos et. al, Journal of Law and the Biosciences, Volume 8, Issue 2, Oct 2021.
- “Governance choices of genome editing patents“, N. Scheinermann and J.S. Sherkow, Frontiers in Political Science, Sep 2021.
- “Genome editing in Latin America: CRISPR Patent and Licensing Policy“, M. Bagley, Discussion Paper No. IDB-DP-00876, Inter-American Development Bank, July 2021.
- “The role of patents and licensing in the governance of human genome editing: a white paper“. D. Matthews et al., Human Genome Editing: A Framework for Governance and Recommendations, Response to the WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing Reports, July 2021.
- “The CRISPR Patent Landscape: Focus on Chinese Researchers“, S. Bire, C. Le Buhan and F. Palazzoli, The CRISPR Journal, Vol. 4, No. 3, June 2021.
- “Open Intellectual Property Models for Plant Innovations in the Context of New Breeding Technologies“, M.A. Kock, Agronomy 2021 11(6) 1218, May 2021.
- “Food system innovations and digital technologies to foster productivity growth and rural transformation“, Food Systems Summit Brief prepared by Research Partners of the Scientific Group – United Nations Food Systems Summit 2021, May 2021.
- “Making Sense of the CRISPR-Cas9 Patent Battle: What Can Start-ups Learn?”, L. Eades and A. Taylor, The Science Entrepreneur Club, May 2021.
- “Who Owns CRISPR in 2021? It’s Even More Complicated Than You Think“, Synbiobeta News, April 2021.
- “Patenting dynamics in CRISPR gene editing technologies“, P. Ganguli, In Nanobiotechnology for Plant Protection, CRISPR and RNAi Systems, Elsevier, 2021, Pages 405-439.
- “CRISPR /Cas9 원천 특허는 누구의 손에?“, Technology Patent Guide by Sunhee Lee, U.S. Attorney, Jan 2021.
- “Patent management: Protecting intellectual property and innovation“, O. Gassmann, M.A. Bader, M.J. Thompson, Springer, 2021.
- “Neue gentechnische Verfahren: Kommerzialisierungspipeline im Bereich Pflanzenzüchtung und Lizenzvereinbarungen.“, Dr. Eva Gelinsky et al., Swiss Federal Office For the Environment, Dec 2020.”
- Les pionnières du “ciseau génétique” Crispr-Cas9 reçoivent le prix nobel de chimie“, Le Figaro, Oct 2020.
- “CRISPR e il future dell’ingegneria genetica in Cina“, F. Silvestri, Torino World Affairs Institute, Sep 2020.
- “Promoting access to medical technologies and innovation – Intersections between public health, intellectual property and trade – 2nd edition“, World Health Organization, July 2020.
- “MPEG LA’s Use of a Patent Pool to Solve the CRISPR Industry’s Licensing Problems“, P. Neville, Utah Law Review, Vol. 2020 Nb. 2 Art. 5, June 2020.
- “10 Technologias emergentes para impulsar a Espana“, Capitulo 2 edicion genetica, June 2020.
- “Democratizing CRISPR? Stories, practices, and politics of science and governance on the agricultural gene editing frontier“, M. Montenegro de Wit, Elem Sci Anth, 8(1), p.9, Feb 2020.
- “The landscape of early clinical gene therapies outside of Oncology“, L. Rittié et al., Molecular Therapy, CellPress, Sep 2019.
- “CRISPR-Cas9: How the Patent Dispute has Transformed Science Innovation“, Cyagen Technical Bulletin, Sep 2019.
- “CRISPR patents by numbers“, Anna Meldolesi, mycrispr.blog, July 2019.
- “A brief guide to the current CRISPR patent landscape”, The Scientist, July 2019.
- “Parity Analysis: Topological Considerations for Patent Valuation and Portfolio Management”, J. Skelley, Chicago-Kent Journal of Intellectual Property, Vol. 18, Issue 3, June 2019.
- “On the relevance of deeper patent office register information for reporting to C-levels and investors – Biotech case studies“, C. Le Buhan, CHPIUG General Assembly, Geneva, June 2019.
- “Gene drives – a report on their science, social aspects, ethics and regulations”, a joint publication by Critical Scientists Switzerland, European Network of Scientists for Social and Environmental Responsibility e.V., and Vereinigung Deutscher Wissenschaftler e.V., May 2019.
- “Getting serious about the challenge of regulating germline gene therapy”, A. Caplan, PLoS Biol 17(4): e3000223. https://doi.org/10.1371/journal.pbio.3000223.
- “CRISPR-Cas9: entre génétique et éthique, où est la place du droit?“, M. Carbon, Faculté de droit et de criminologie, Université catholique de Louvain, 2019.
- “China’s algricultural policies: trade, investment, safety, and innovation“, U.S.-China Economic And Security Review Commission 2018 Annual Report to Congress, Chapter 1, Section 3, Nov 2018.
- “Use the patent system to regulate gene editing”, Prof. Shobita Parthasarathy, University of Michigan, Nature, Oct 2018.
- “Governance of Digital Sequence Information And Impacts For Access And Benefit Sharing 2018“, Report, Centre for the Study of Science and Innovation Policy, University of Saskatchewan, Canada, Oct 2018.
- “On the relevance of deeper patent office register information for reporting to C-levels and investors – Biotech case studies“, C. Le Buhan, CEPIUG 10th anniversary conference, Milano, Sep 2018.
- “Surveying the CRISPR patent war“, Expert analysis by Michael Stramiello, Law360, May 2018.
- “ゲノム編集技術として注目を浴びているCRISPR技術の日米における特許の状況”, TMI Associate Newsletter, No.35, May 2018.
- “Agricultural biotechnology policy in China“, Prof. Carl Pray, Rutgers University, Hearing of U.S. China Economic And Security Review Commission on U.S.-China Food Policy, Apr 2018.
- “This Court Battle Will Decide Who Will Make a Fortune From Gene-Editing Tech“, Bloomberg, Apr 2018
- “European patent office revokes Broad Institute CRISPR patent“, BioWorld, Jan 2018
- “MPEG-LA: What Could a Patent Pool Do for the Promise of CRISPR?“, Slides presentation by K. Newman at the LES France 2017 Licensing Conference, Paris, Dec 2017.
- “Bitter CRISPR patent war intensifies“, Nature, Oct 2017.
- “Flux and Uncertainty in the CRISPR Patent Landscape“, The Scientist, Oct 2017 issue.
- “MPEG-LA: What Could a Patent Pool Do for the Promise of CRISPR?“, Video Presentation by K. Newman – Knowledge Ecology International Workshop, Sep 2017.
- “CRISPR: supercharging genome editing”, H. Cline, Bioscience Law Review Vol.16, Issue 1, p.3 – Special issue on genome editing – May 2017.
- Département fédéral de la défense, de la protection de la population et des sports, Armasuisse, Colloque Deftech du 3 mai 2017 sur CRISPR-Cas9 : “CRISPR et brevets: quel paysage pour ce couteau Suisse des biotechnologies ? » – Dr. Fabien Palazzoli, invited speaker.
- Cell Line Development & Engineering Conference – 23-25 April 2017, Amsterdam : «Patent information and CRISPR : what can we learn from the CRISPR patent and licensing landscape ? » – Dr. Fabien Palazzoli, invited speaker.
- “Navigating the CRISPR IP landscape in Europe”, World Intellectual Property Review and HGF Webinar, April 2017.
- « CRISPR Patent Pool – An opportunity to leverage experience from patent pool models to help CRISPR reach its full potential », K. Neuman, American Intellectual Property Association AIPLA, April 2017.
- « Les enjeux économiques, environnementaux, sanitaires et éthiques des biotechnologies à la lumière des nouvelles pistes de recherche », Office parlementaire d’évaluation des choix scientifiques et technologiques, Assemblée Nationale Française, Avril 2017.
- « Etape cruciale dans une guerre de brevets valant des milliards », Emission Radio Suisse RTS Forum, Feb 2017.
- “Europe-outpaced-in-race-to-commercialise-gene-editing-technologies”, Science Business, Feb 2017.
- “The battle to own the CRISPR–Cas9 gene-editing tool”, World Intellectual Property Organization Magazine, 02/2017.
- “Why the CRISPR patent verdict isn’t the end of the story”, Nature, Feb 2017.
- “The commercialization of genone-editing technologies“, Critical Reviews in Biotechnology, Jan 2017
- “Blessed are the copy editors”, Fortune, Oct 2016.
- “CRISPR-based startups are rushing to IPO and don’t seem to care that we don’t know who officially owns CRISPR”, Quartz, Oct 2016.
- « Premier round de la guerre des brevets portant sur la chirurgie du gène », Le Temps, Sept 2016
- ”Titanic clash over CRISPR patents turns ugly”, Nature, Sept 2016.
- “That other CRISPR patent dispute”, The Scientist, Aug 2016.
- « L’arrivée des patent trolls », Le Temps, Feb 2016.
- “The gene-editing tool on every drugmaker’s wish list this year”, Bloomberg, Dec 2015.